22.Issue 06 june 26 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 13, Issue : 06, June – 2026

Title:

A META-ANALYSIS OF PREVALENCE, RISK FACTORS, COMORBIDITIES AND TREATMENT PATTERNS IN MYOCARDIAL INFARCTION

Authors :

A.Gunalatha *, T.Mngilal,Shaista Tabassum, K.Nagalaxmi, B.Anusha, J.Anand Kumar, Ali Abdul Basith

Abstract :

Myocardial Infarction (MI) remains one of the leading causes of morbidity and mortality worldwide and represents a major public health challenge. This systematic review aimed to evaluate the prevalence, demographic characteristics, associated comorbidities, risk factors, and treatment approaches among patients with myocardial infarction. Data from 18 published studies comprising more than 85,725 patients were analyzed. The findings demonstrated a marked male predominance, with 72.4% males and 27.6% females among the study population. The findings demonstrated a higher prevalence of myocardial infarction among males, with most patients belonging to the middle-aged and elderly population. Hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, and obesity were the most commonly reported comorbidities. Major risk factors included smoking, advancing age, sedentary lifestyle, alcohol consumption, genetic predisposition, and psychosocial stress. Treatment modalities varied across studies and included antiplatelet agents, statins, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytic therapy, and percutaneous coronary intervention (PCI), which remain the cornerstone of contemporary myocardial infarction management. The reviewed studies consistently emphasized the importance of early diagnosis, prompt treatment, and effective risk-factor modification in improving clinical outcomes. This review highlights the substantial burden of myocardial infarction and underscores the need for comprehensive preventive strategies, multidisciplinary management, and adherence to evidence-based therapies to reduce mortality and improve patients’ quality of life.
Keywords: Myocardial Infarction; Acute Coronary Syndrome; Cardiovascular Risk Factors; Hypertension; Diabetes Mellitus; Dyslipidemia; Smoking; Comorbidities; Treatment Outcomes; Percutaneous Coronary Intervention; Mortality; Systematic Review.

Cite This Article:

Please cite this article in press A.Gunalatha et al., A Meta-Analysis Of Prevalence, Risk Factors, Comorbidities And Treatment Patterns In Myocardial Infarction., Indo Am. J. P. Sci, 2026; 13(06).

REFERENCES:

1. Mayo Clinic (n.d.) Heart attack: Symptoms and causes. Available at: https://www.mayoclinic.org/diseases-conditions/heartattack/symptoms-causes/syc-20373106
2. Sahu, A. et al. (n.d.) ‘Myocardial infarction: A comprehensive review’, Semantic Scholar PDF. Available at: https://pdfs.semanticscholar.org/c71a/7a13668ce3109ff3cbad3690 e7b39ee615cf.pdf.
3. Biology Insights (n.d.) Myocardial infarction classification and its different types. Available at: https://biologyinsights.com/myocardialinfarction-classification-and-its-different-types/.
4. Patient.info (n.d.) Heart attack (myocardial infarction). Available at: https://patient.info/heart-health/heart-attack-myocardialinfarction-leaflet .
5. Biology Insights (n.d.) Myocardial infarction classification and its different types. Available at: https://biologyinsights.com/myocardialinfarction-classification-and-its-different-types/ .
6.Sharma, R. et al. (n.d.) ‘Myocardial Infarction: Risk Factors, Pathophysiology, Classification, Assessment and Management’, Auctores Journal. Available at: https://www.auctoresonline.org/article/myocardial-infarction-riskfactors-pathophysiology-classification-assessment-andmanagement .
7. Apollo Hospitals (n.d.) Myocardial infarction. Available at: https://www.apollohospitals.com/diseases-andconditions/myocardial-infarction.
8. Mayo Clinic (n.d.) Heart attack: Diagnosis and treatment. Available at: https://www.mayoclinic.org/diseases-conditions/heartattack/diagnosis-treatment/drc-20373112 .
9. American Heart Association (n.d.) Life after a heart attack: Lifestyle changes for heart attack prevention. Available at: https://www.heart.org/en/health-topics/heart-attack/life-after-aheart-attack/lifestyle-changes-for-heart-attack-prevention.
10. Gupta, M.D. et al. (2020) ‘Risk factors for myocardial infarction in very young South Asians’, Current Opinion in Endocrinology, Diabetes and Obesity, 27(2), pp. 87–94. Available at: https://pubmed.ncbi.nlm.nih.gov/32073427/ .
11. Reed, G.W. et al. (2017) ‘Acute myocardial infarction’, The Lancet, 389(10065), pp. 197–210. Available at: https://pubmed.ncbi.nlm.nih.gov/27502078/ .
12. Pasupathy, S. et al. (2015) ‘Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries’, Circulation, 131(10), pp. 861–870. Available at: https://pubmed.ncbi.nlm.nih.gov/36075485/ .
13. Collet, J.P. et al. (2023) ‘2023 ESC Guidelines for the management of acute coronary syndromes’, European Heart Journal, 44(38), pp. 3720–3826. Available at: https://pubmed.ncbi.nlm.nih.gov/39658094/.
14. Ibanez, B. et al. (2023) ‘Updated ESC Guidelines for myocardial infarction management’, European Heart Journal, 44(41), pp. 3945– 4042. Available at: https://pubmed.ncbi.nlm.nih.gov/39818676/
15. Thygesen, K. et al. (2018) ‘Fourth universal definition of myocardial infarction’, European Heart Journal, 40(3), pp. 237–269. Available at: https://pubmed.ncbi.nlm.nih.gov/39622590/ .
16. Chapman, A.R. et al. (2019) ‘Long-term outcomes in patients with type 2 myocardial infarction’, Circulation, 137(12), pp. 1236– 1245. Available at: https://pubmed.ncbi.nlm.nih.gov/31327544/ .
17. Devereaux, P.J. et al. (2011) ‘Perioperative myocardial infarction after noncardiac surgery’, New England Journal of Medicine, 365(21), pp. 1914–1923.
18. Baron, T. et al. (2015) ‘Type 2 myocardial infarction in clinical practice’, European Heart Journal, 36(20), pp. 1256–1263. Available at: https://pubmed.ncbi.nlm.nih.gov/26599804/ .
19.DeFilippis, A.P. et al. (2019) ‘Assessment and treatment of patients with type 2 myocardial infarction’, Circulation, 140(20), pp. 1661–1678. Available at: https://pubmed.ncbi.nlm.nih.gov/30736935/ .
20. Januzzi, J.L. et al. (2021) ‘Cardiac biomarkers in myocardial infarction’, Journal of the American College of Cardiology, 78(4), pp. 345–356. Available at: https://pubmed.ncbi.nlm.nih.gov/34053623/
21. Ibanez, B. et al. (2017) ‘2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation’, European Heart Journal, 39(2), pp. 119– 177. Available at: https://pubmed.ncbi.nlm.nih.gov/30228871/ .
22. O’Gara, P.T. et al. (2013) ‘2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction’, Circulation, 127(4), pp. e362–e425. Available at: https://pubmed.ncbi.nlm.nih.gov/27251920/ .
23. Collet, J.P. et al. (2021) ‘2020 ESC Guidelines for the management of acute coronary syndromes’, European Heart Journal, 42(14), pp. 1289–1367. Available at: https://pubmed.ncbi.nlm.nih.gov/33412179/ .
24. Antman, E.M. et al. (2008) ‘Management of ST-elevation myocardial infarction’, Journal of the American College of Cardiology, 51(2), pp. 210–247. Available at: https://pubmed.ncbi.nlm.nih.gov/31902409/ .
25. Bozkurt, B. et al. (2021) ‘Myocarditis and myocardial infarction following COVID-19 vaccination’, Circulation, 144(6), pp. 471–484